Company intelligence / Profile preview

Aquinox Pharmaceuticals

Vancouver, British Columbia, Canadaaqxpharma.com ↗
Ownership
Private
Development stage
Other
01

Overview

AQX-1125 showed positive trends in primary endpoint and statistically significant changes on multiple secondary endpoints in Phase 2 LEADERSHIP trial for BPS/IC. However, the Phase 2 KINSHIP trial for atopic dermatitis failed to demonstrate efficacy.

Therapeutic areas
OncologyNephrologyImmunologyDermatologyHematology
Modalities
Small moleculesDe novo protein therapeutics
Industry
Biotech

Beyond the preview

Go deeper on Aquinox Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aquinox Pharmaceuticals.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call